Variations in serum concentrations of sunitinib and its metabolites in patients receiving long-term sunitinib treatment
This study showed that the C/D ratio of sunitinib decreased by half over time in half of the patients who received long-term sunitinib treatment despite continuing the same dose. Therefore, serum concentrations of sunitinib and its metabolites should be monitored periodically in patients receiving long-term treatment to prevent decrease in serum sunitinib concentrations.
Authors
- Y. Ishikawa (ORCID: https://orcid.org/0000-0002-1978-0284)
- Mari Kogo (ORCID: https://orcid.org/0000-0001-7553-0872)
- Jun Morita (ORCID: https://orcid.org/0000-0002-4857-8683)
- Masayuki Ohbayashi (ORCID: https://orcid.org/0000-0002-9862-2400)
- Miki Takenaka Sato (ORCID: https://orcid.org/0000-0002-0474-2007)
- Noriko Kohyama (ORCID: https://orcid.org/0000-0002-4681-5833)
- Yoshio Ogawa (ORCID: https://orcid.org/0000-0001-9542-2924)
- Koujirou Yamamoto
- Yoshiko Maeda (ORCID: https://orcid.org/0000-0001-9914-6242)
- Hideaki Yashima (ORCID: https://orcid.org/0000-0002-8982-2312)
- Takashi Fukagai (ORCID: https://orcid.org/0000-0003-0261-6303)
- Takuya Araki (ORCID: https://orcid.org/0009-0005-9162-5405)
Institutions
- SHOWA Medical University (JP)
- Gunma University (JP)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- SHOWA Medical University Fujigaoka Hospital (JP)
- SHOWA Medical University Hospital (JP)
- Gunma University Hospital (JP)
- Showa Pharmaceutical University (JP)
Publication Details
- Journal
- Cancer Chemotherapy and Pharmacology
- Published
- 2024-12-26
- DOI
- https://doi.org/10.1007/s00280-024-04741-w
- Citations
- 3
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Japan Society for the Promotion of Science